비호지킨림프종 치료제 시장 : 현황 분석과 예측(2023-2030년)

The non-Hodgkin lymphoma (NHL) therapeutics market is a rapidly growing sector in the healthcare industry, driven by advancements in research and development, as well as an increasing prevalence of NHL worldwide. Non-Hodgkin lymphoma refers to a group of cancers that originate in the lymphatic system, leading to abnormal growth of lymphocytes, which are white blood cells responsible for immune function. The market for NHL therapeutics has witnessed significant growth over the years, primarily due to the rising incidence of NHL globally. According to the American Cancer Society, it is estimated that approximately 81,560 new cases of NHL will be diagnosed in the United States alone in 2022. Moreover, factors such as an aging population and environmental factors contribute to the increasing prevalence of NHL, driving the demand for effective treatment options. Further, the development of personalized medicine and precision oncology has also significantly impacted the NHL therapeutics market.

The Non-Hodgkin Lymphoma Therapeutics Market is expected to grow at a strong CAGR of 7.7% during the forecast period owing to the growing prevalence of non-Hodgkin lymphoma. TNon-Hodgkin lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which is responsible for carrying lymph fluid throughout the body. It is characterized by the abnormal growth of lymphocytes, a type of white blood cell. The prevalence of non-Hodgkin lymphoma has been steadily increasing worldwide in recent years, posing significant challenges to public health. According to American Cancer Society, about 80,550 people (44,880 males and 35,670 females) will be diagnosed with NHL in 2023. This includes both adults and children As per the European Cancer Information System (ECIS), in 2020, there were an estimated 159,600 new cases of NHL in the European Union alone.

Based on therapy type, the market is categorized into chemotherapy, radiation therapy, targeted therapy, and immune therapy. The immune therapy held a significant share of the market in 2022, which is attributed to the increasing adoption of targeted therapy, the emergence of cost-effective biosimilars, increasing demand for monoclonal antibodies, and promising response in the treatment of non-Hodgkin lymphoma. In addition, rising number of clinical trials and growing investment by pharmaceutical companies is also driving the segment growth during the forthcoming period.

Based on cell type, the market is bifurcated into B-cell lymphoma and T-cell lymphoma. The B cell lymphoma segment plays a significant role in the non-Hodgkin lymphoma therapeutics market due to several driving factors. First and foremost, the incidence of B cell lymphoma is relatively high among all the subtypes of non-Hodgkin lymphoma, making it a crucial area of focus for researchers and pharmaceutical companies. Furthermore, advancements in understanding the molecular and genetic characteristics of B cell lymphomas have led to the development of targeted therapies.

Based on the route of administration, the market is bifurcated into oral and injectable. The injectable therapeutics segment plays a crucial role in the non-Hodgkin lymphoma therapeutics market, driven by several factors. Firstly, injectable therapeutics offer significant advantages in terms of convenience and administration. Unlike oral medications, injectable therapies can be directly administered by healthcare professionals, ensuring precise dosage and optimal drug delivery. This is especially important in non-Hodgkin lymphoma, where timely and accurate treatment is crucial. Secondly, injectable therapeutics in the non-Hodgkin lymphoma market often consist of targeted therapies and immunotherapies, which have shown remarkable efficacy in treating this type of cancer.

Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacies segment is anticipated to grow with high CAGR during the forecast period. Several driving factors contribute to this upward trend. Firstly, the convenience offered by online pharmacies plays a crucial role in their popularity. Patients no longer need to visit physical stores or clinics to purchase their medications. Secondly, online pharmacies often provide a wider range of products compared to brick-and-mortar stores. Patients can access both branded and generic medications, enabling them to choose options that fit their specific requirements and budget.

For a better understanding of the market adoption of the non-Hodgkin lymphoma therapeutics industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held a dominant share of the market in 2022. In North America, the prevalence of non-Hodgkin lymphoma has been steadily increasing in recent years, contributing to the growth of the therapeutics market. Factors such as the aging population, environmental factors, and genetic predisposition have been identified as potential causes for this rise. The market is supported by a well-established healthcare infrastructure, advanced research facilities, and a strong emphasis on medical innovation within the region. North America is home to several prominent pharmaceutical companies that actively contribute to the development of novel therapeutics and treatment modalities.

Some of the major players operating in the market include: Merck KGaA; BeiGene, Ltd.; F. Hoffmann-La Roche Ltd; Bristol Myers Squibb; Eisai Co., Ltd.; AstraZeneca; Gilead Sciences; Novartis AG; Baxter; and Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Non-Hodgkin Lymphoma Therapeutics Market
• 2.2. Research Methodology of the Non-Hodgkin Lymphoma Therapeutics Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET COVID-19 IMPACT

6 GLOBAL NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY THERAPY TYPE

• 7.1. Chemotherapy
• 7.2. Radiation Therapy
• 7.3. Targeted Therapy
• 7.4. Immune Therapy

8 MARKET INSIGHTS BY CELL TYPE

• 8.1. B-Cell Lymphoma
• 8.2. T-Cell Lymphoma

9 MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

• 9.1. Oral
• 9.2. Injectable

10 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 10.1. Hospital Pharmacies
• 10.2. Retail Pharmacies
• 10.3. Online Pharmacies

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. United States
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. France
  • 11.2.3. U.K.
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia Pacific
• 11.4. Rest of World

12 NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET OPPORTUNITIES

14 NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Porter's Five Forces Analysis
• 17.2. Competitive Landscape

18 COMPANY PROFILED

• 18.1. Merck KGaA
• 18.2. BeiGene, Ltd.
• 18.3. F. Hoffmann-La Roche Ltd
• 18.4. Bristol Myers Squibb
• 18.5. Eisai Co., Ltd.
• 18.6. AstraZeneca
• 18.7. Gilead Sciences
• 18.8. Novartis AG
• 18.9. Baxter
• 18.10. Teva Pharmaceutical Industries Ltd.

19 DISCLAIMER